Hodgkin's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Hodgkin's Disease, including details on causes, cancer, lymphoma, stages, symptoms.

Volume 2 (2005), Issue 10 (October)

1. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.
   Lancet Oncol, 6(10): 773-9. [Abstract] [Full-text]
2. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
   Int J Radiat Oncol Biol Phys, 63(3): 860-5. [Abstract] [Full-text]
3. Family history of hematopoietic malignancy and risk of lymphoma.
   J Natl Cancer Inst, 97(19): 1466-74. [Abstract] [Full-text]
4. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
   J Natl Cancer Inst, 97(19): 1428-37. [Abstract] [Full-text]
5. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma.
   Ann Hematol, 84(10): 661-6. [Abstract] [Full-text]
6. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
   J Clin Oncol, 23(30): 7555-64. [Abstract] [Full-text]
7. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study.
   J Clin Oncol, 23(30): 7604-13. [Abstract] [Full-text]
8. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.
   J Clin Oncol, 23(30): 7614-20. [Abstract] [Full-text]
9. Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab.
   Leuk Lymphoma, 46(11): 1613-7. [Abstract] [Full-text]
10. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
    Leuk Lymphoma, 46(11): 1581-91. [Abstract] [Full-text]
11. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.
    Leuk Lymphoma, 46(11): 1561-7. [Abstract] [Full-text]
12. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase.
    Mod Pathol, 18(11): 1440-7. [Abstract] [Full-text]
13. Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas.
    Mod Pathol, 18(11): 1448-53. [Abstract] [Full-text]
14. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
    Onkologie, 28(11): 567-71. [Abstract] [Full-text]
15. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).
    Int J Radiat Oncol Biol Phys, 63(4): 1184-90. [Abstract] [Full-text]
16. High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
    J Clin Oncol, 23(31): 7994-8002. [Abstract] [Full-text]
17. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.
    J Clin Oncol, 23(31): 8003-11. [Abstract] [Full-text]

© 2004-2012 Hodgkin's Disease Research Today. All Rights Reserved.